bionanogenomics.com (BNGO) Long-Term Debt to Capital Ratio
This BNGO price chart illustrates the trend of a metric currently at 0.19. Bionano Genomics, Inc. (BNGO) develops exclusive DNA structure analysis systems, leveraging a unique market advantage. The company generates steady revenue through the recurring sale of specialized chips to equipment owners. However, a reduction in scientific grants is forcing the business to implement preferential leasing terms and lower the cost of its hardware.
Analytical breakdowns for Bionano Genomics, Inc.
The financial stability of Bionano Genomics, Inc. (BNGO) is based on the balance between borrowed funds and equity. This ratio measures the proportion of liabilities with a maturity of over one year, determining the business's degree of dependence on external lending. It is critical for investors to evaluate this leverage to understand bankruptcy risks. Amid efforts to combat cash burn and optimize expenses, such a metric confirms the efficiency of resource management. By analyzing the long-term debt structure relative to equity, one can assess the margin of safety for the Saphyr platform.